|Last Update: 05/20/13 - 4:02 PM EDT|
|YTD Performance: 25.68%|
|Previous Close: $68.90|
|52 Week Range: $49.43 - $69.81|
|Oustanding Shares: 378,056,811|
|Market Cap: 26,108,603,368|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||16||16||21||19|
|Growth Rate (Year over Year)||5.04%||4.06%||5.53%||8.75%|
Safety stocks aren’t every going to be crushed, but could certainly stumble.
SYK was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $67 price target.
SYK was downgraded to Neutral from Buy, UBS said. Reasonably valued and strong recent move.
SYK was downgraded from Buy to Neutral, Mizuho said. Orthopedic market will likely remain lackluster in 2013.
Shares of SYK now seen reaching $65, BMO Capital Markets said. Estimates also increased folliwng a good recon quarter. Market Perform rating.
Shares of SYK now seen reaching $66, Jefferies said. Encouraging signs in the quarter. Hold rating.
Good news seems to be cropping up all over the place this morning.
This investment pro may not be as high-profile as others, but he sure can pick 'em.
Shares of SYK downgraded to Perform from Outperform, Oppenheimer said. $56 price target. Lower near- term drivers.
SYK estimates were cut through 2014, BMO Capital said. Company is seeing slower growth in Europe. Market Perform rating and new $55 price target.